Number Authors Age Sex Diagnosis of cancer Treatment and concurrent medications Antiangiogenic agents Symptoms Clinical presentation Site of MRONJ Time to MRONJ Predisposing factors Management of MRONJ Outcomes Definition of disease resolution Estilo et al. [23 ] 51 F Metastatic breast cancer Mastectomy Bevacizumab Jaw discomfort Bone exposure Mandible 18 weeks None Surgical treatment Disease resolution (few weeks) Complete mucosal coverage Estilo et al. [23 ] 33 F Glioblastoma multiforme Surgical resection Bevacizumab Jaw pain Bone exposure Mandible 11 weeks None None Persistent bone exposure — Greuter et al. [24 ] 63 F Metastatic breast cancer Liposomal-doxorubicin Bevacizumab Maxillary pain Bone exposure Maxilla 2 months Extraction due to dental infection Surgical treatment Disease resolution Not specified Serra et al. [25 ] 64 M Metastatic non-small-cell lung cancer Pneumectomy Bevacizumab Jaw pain Bone exposure Mandible 1 week Extraction Surgical treatment Persistent bone exposure — Guarneri et al. [19 ] NA NA Metastatic breast cancer Docetaxel Bevacizumab NA Bone exposure Mandible 7 months None Surgical treatment Disease resolution Complete mucosal coverage Guarneri et al. [19 ] NA NA Metastatic breast cancer Docetaxel Bevacizumab NA Bone exposure NA 2 months None NA NA — Brunamonti26 ] 47 M Adenocarcinoma of parotid gland Surgical treatment Bevacizumab Jaw pain, paraesthesia Bone exposure Mandible 16 months Symptomatic eruption of lower third molar Surgical treatment Persistent bone exposure — Bettini et al. [27 ] 57 F Metastatic non-small-cell lung cancer Gemcitabine Bevacizumab Jaw pain, Bone exposure Mandible 2 months Periodontal infection Amoxicillin with clavulanate Disease resolution Complete mucosal coverage Dişel et al. [28 ] 51 M Metastatic colon cancer 5-Fluorouracil Bevacizumab Jaw pain, ulcer, difficulty in chewing Bone exposure Mandible NA None Surgical treatment NA — Sato et al. 29 ] 67 M Metastatic sigmoid colon cancer Surgical treatment Bevacizumab Jaw pain Nonexposed MRONJ Maxilla 3 months Extraction Surgical treatment Disease resolution Complete mucosal coverage Fusco et al. [30 ] 60 M Metastatic rectal cancer Surgical treatment Bevacizumab Jaw pain Bone exposure Mandible 9 months Extraction Antibiotics NA — Tzermpos et al. [31 ] 69 M Metastatic non-small-cell lung cancer Carboplatin Bevacizumab Jaw pain, discomfort, paraesthesia Bone exposure Mandible 3 years Denture Surgical treatment Disease resolution (8 weeks) Complete mucosal coverage Abel Mahedi 32 ] 55 F Non-small-cell lung cancer Corticosteroids Bevacizumab Asymptomatic Bone exposure Maxilla 1.5 months after starting bevacizumab Extraction Conservative treatment Disease resolution Not specified Abel Mahedi 32 ] 66 M Glioblastoma multiforme Corticosteroids Bevacizumab Pain Nonexposed MRONJ Mandible 1.5 months after starting bevacizumab Trauma Conservative treatment Disease resolution Not specified Ponzetti et al. [33 ] 64 F Metastatic colorectal cancer 5-Fluorouracil Aflibercept Spontaneous teeth loss with purulent discharge Bone exposure Mandible 22 weeks Periodontal infection Laser treatment Persistent bone exposure — Mawardi et al. [34 ] 43 M Metastatic colorectal cancer 5-Fluorouracil Aflibercept Jaw pain Bone exposure Mandible 32 weeks after starting aflibercept None Amoxicillin Persistent bone exposure — Mawardi et al. [34 ] 63 M Metastatic carcinoid cancer NA Aflibercept Asymptomatic Bone exposure Mandible 46 weeks after starting aflibercept None Amoxicillin with clavulanate Persistent bone exposure (2.5 months) — Mawardi et al. [34 ] 51 M Metastatic esophageal cancer 5-Fluorouracil Aflibercept Jaw pain Bone exposure Mandible 14 weeks after starting aflibercept Extraction Amoxicillin Persistent bone exposure (2 months) - Zarringhalam et al. [35 ] 47 M Metastatic colorectal, peritoneum, liver, and pelvic cancer None Aflibercept Asymptomatic Bone exposure Mandible 4 weeks after starting aflibercept None Surgical treatment Persistent bone exposure (12 weeks) — Nicolatou-Galitis36 ] 64 F Metastatic renal cell cancer Nephrectomy Sunitinib Jaw pain Bone exposure Mandible 4 years Denture Amoxicillin Disease resolution (3 months) Complete mucosal coverage Fleissig et al. [37 ] 58 F Metastatic renal cell cancer Nephrectomy Sunitinib 50 mg/day for 4 weeks on and Limited mouth opening, submandibular swelling, pain Bone exposure Mandible 10 months Extraction Amoxicillin with clavulanate (IV) Disease resolution (18 weeks) Complete mucosal coverage Melloni et al. [38 ] 62 M Metastatic renal cell cancer NA Sunitinib 50 mg/day for 4 weeks on and Jaw pain and infected lesion to the cutaneous side of the jaw Bone exposure Mandible 5 years None Surgical treatment Disease resolution (12 months) Complete mucosal coverage Tempia Valenta 39 ] 51 F Medullary thyroid cancer NA Cabozantinib NA Bone exposure Mandible 6 months Extraction Surgical treatment Disease resolution (22 months) Not specified Marino et al. [40 ] 51 F Medullary thyroid cancer Thyroidectomy Cabozantinib Asymptomatic Bone exposure Mandible 3 months Extraction due to dental infection Surgical treatment Disease resolution Complete mucosal coverage Garuti et al. [41 ] 74 M Metastatic hepatocellular carcinoma Furosemide Sorafenib Asymptomatic Nonexposed MRONJ Mandible 3 months after starting sorafenib None Interruption of sorafenib Persistent bone exposure — Abel Mahedi 32 ] 53 F Acute lymphoblastic leukemia Corticosteroids Dasatinib Pain Bone exposure Mandible 5 months after starting dasatinib Extraction Surgical treatment (block resection) Disease resolution Not specified Parti et al. [42 ] 60 M Metastatic renal cell cancer Nephrectomy Temsirolimus NA Bone exposure Mandible 3 months Extraction Interruption of temsirolimus NA — Yamamoto 43 ] 80 F Metastatic breast cancer Capecitabine Everolimus Jaw pain, localised heat, tenderness Bone exposure Mandible 2 months after starting everolimus None Interruption of everolimus Persistent bone exposure (2 months) — Agostino et al. [44 ] 73 M Metastatic renal cell cancer Nephrectomy (1) Sunitinib NA NA NA 12 months NA Interruption of bevacizumab NA — Koch et al. [45 ] 59 M Metastatic renal cell cancer Nephrectomy (1) Sorafenib Asymptomatic Bone exposure Mandible 51 months Extraction Surgical treatment Disease resolution Complete mucosal coverage Santos-Silva et al. [46 ] 61 M Metastatic renal cell cancer Nephrectomy (1) Bevacizumab Jaw pain Bone exposure Mandible 55 weeks None Chlorhexidine mouthwash 0.12% Disease resolution (3 months) The absence of exposed necrotic bone Pakosch et al. [47 ] 53 F Pancreatic cancer Surgical treatment (1) Bevacizumab Jaw pain Bone exposure Mandible 4 months Denture Surgical treatment Disease resolution (2 months) Complete mucosal coverage Jung [48 ] 62 F Renal cell cancer Nephrectomy (1) Pazopanib Gingival bleeding and sore gum Bone exposure Mandible 7 weeks after starting everolimus Dental implant Cephalosporin Disease resolution Complete mucosal coverage Patel et al. [49 ] 67 M Metastatic renal cell cancer Nivolumab (1) Pazopanib Asymptomatic Bone exposure Maxilla 1 months after starting axitinib None Hydrogen peroxide mouthwash NA — Abel Mahedi 32 ] 70 M Renal cell cancer Corticosteroids (1) Sunitinib Asymptomatic Bone exposure Mandible 10 months after starting sunitinib, everolimus was commenced Extraction Conservative treatment Persistent bone exposure —
